Deanna L. Kelly is Professor of Psychiatry at University of Maryland Baltimore School of Medicine and Affiliate Professor in the School of Pharmacy. She is currently Director and Chief of the Treatment Research Program at the Maryland Psychiatric Research Center. Dr. Kelly received her bachelor’s and doctoral degrees in pharmacy, at Duquesne University. She completed residency training in psychiatric pharmacy practice at the University of Maryland.

Dr. Kelly’s research focuses on treatment research, mostly conducting clinical trials with innovative treatment targets and for understudied populations. Dr. Kelly has completed one of the few large clinical trials in women with schizophrenia, and she runs a unique large multinational trial to improve outcomes with clozapine treatment in people of African descent. She has completed a handful of unique studies in specific schizophrenia subgroups and she is running the only inpatient clinical trial focusing on the removal of dietary gluten in people with schizophrenia who have antibodies to the gluten protein, gliadin. The overarching goal of her research is to help develop personalized and beneficial treatments to enable people with schizophrenia to have access to potentially life altering treatments.

Dr. Kelly has co-authored or authored 16 books and book chapters and has published more than 160 peer-reviewed manuscripts. She serves as a founding and current Associate Editor for Clinical Schizophrenia and Related Psychoses, is a member of the American College of Neuropsychopharmacology and currently is the President for the College of Psychiatric and Neurologic Pharmacists.

Prizewinner Video: